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This article highlights trends and changes in lung and
heart–lung transplantation in the United States from
1999 to 2008. While adult lung transplantation grew
significantly over the past decade, rates of heart–lung
and pediatric lung transplantation have remained low.
Since implementation of the lung allocation score
(LAS) donor allocation system in 2005, decreases in the
number of active waiting list patients, waiting times
for lung transplantation and death rates on the wait-
ing list have occurred. However, characteristics of recip-
ients transplanted in the LAS era differed from those
transplanted earlier. The proportion of candidates un-
dergoing lung transplantation for chronic obstructive
pulmonary disease decreased, while increasing for
those with pulmonary fibrosis. In the LAS era, older,
sicker and previously transplanted candidates under-
went transplantation more frequently compared with
the previous era. Despite these changes, when com-
pared with the pre-LAS era, 1-year survival after lung
transplantation did not significantly change after LAS
inception. The long-term effects of the change in the
characteristics of lung transplant recipients on overall
outcomes for lung transplantation remain unknown.
Continued surveillance and refinements to the LAS
system will affect the distribution and types of can-
didates transplanted and hopefully lead to improved
system efficiency and outcomes.
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Introduction
This article highlights trends and changes in lung and heart–
lung transplantation in the United States from 1999 to
2008. The article builds upon previous Annual Reports (1).
In addition to providing an update on generally reported
information, this article addresses issues not previously
covered in the Scientific Registry of Transplant Recipients’
(SRTR) Report on the State of Transplantation. The article
uses data from the 2009 Organ Procurement and Trans-
plantation Network (OPTN)/SRTR Annual Report (2) and
data from special analyses performed by the SRTR. The
reader may view the 2009 OPTN/SRTR Annual Report ta-
bles online at: http://www.ustransplant.org.
In the United States, transplant programs register accept-
able lung transplant candidates with the OPTN. Whereas
time on the lung transplant waiting list primarily priori-
tized donor lung allocation prior to the implementation of
the lung allocation score (LAS) system, on May 4, 2005
the LAS system began using medical urgency and ex-
pected outcome to prioritize donor lung allocation. The
LAS, ABO blood group and distance from the donor hos-
pital determine the order for making donor lung offers to
lung transplant candidates ages 12 years and older. Pe-
diatric candidates under age 12 continue to receive lung
offers based on the amount of time they have spent wait-
ing for a lung transplant, ABO compatibility and distance
from the donor hospital. In addition, the system priori-
tizes pediatric donor offers to age-matched pediatric age
groups (age less than 12 years and age 12–17 years)
(3–5).
For each candidate, the LAS algorithm estimates the ex-
pected number of days lived during the next year on the
waiting list without a transplant (i.e. waiting list urgency es-
timate) and the number of days lived during the first year
after transplantation (i.e. posttransplant survival estimate).
The LAS algorithm calculates the net transplant benefit by
subtracting the expected days lived on the waiting list with-
out a transplant over the next year from the expected days
lived with a transplant over the next year. The net transplant
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Table 1: Lung allocation score (LAS) primary diagnostic groupings and clinical diagnoses for lung transplant candidates
LAS lung disease primary diagnostic grouping Clinical diagnosis
Group A
(obstructive lung disease)











Sarcoidosis with mean pulmonary artery (PA) pressure ≤ 30 mm Hg
Alpha-1-antitrypsin deficiency (A1ATD)















Eisenmenger’s syndrome: atrial septal defect (ASD)
Eisenmenger’s syndrome: ventricular septal defect (VSD)
Eisenmenger’s syndrome: patent ductus arteriosus (PDA)
Eisenmenger’s syndrome: multiple congenital anomalies
Eisenmenger’s syndrome: other specific




(cystic fibrosis or immunodeficiency disorders)














Acute respiratory distress syndrome (ARDS)/pneumonia
Bronchiolitis obliterans and organizing pneumonia (BOOP)
Bronchoalveolar carcinoma (BAC)
Carcinoid tumorlets







Lymphocytic interstitial pneumonia (LIP)
Continued
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Table 1: Continued
LAS lung disease primary diagnostic grouping Clinical diagnosis
Lupus
Mixed connective tissue disease





Surfactant protein B deficiency
Teratoma
Lung retransplant/graft failure: non-specific
Lung retransplant/graft failure: obliterative bronchiolitis
Lung retransplant/graft failure: restrictive
Lung retransplant/graft failure: acute rejection
Lung retransplant/graft failure: obstructive
Lung retransplant/graft failure: primary graft failure
Lung retransplant/graft failure: other specify
Idiopathic pulmonary fibrosis (IPF)
Sarcoidosis with mean PA pressure > 30 mm Hg
Rheumatoid disease
Occupational lung disease other specify cause
Obliterative bronchiolitis (non-retransplant)
Pulmonary fibrosis other specify cause
Source: Revision to policy 3.7.6.1
benefit minus the transplant urgency determines the LAS
(after normalization of the raw allocation score). The LAS
ranges from a low of zero to a high of 100. Patients with
the highest LAS have the highest priority for receiving a
donor lung offer (3–5).
Transplant center staff members enter clinical data in the
OPTN data system for specific variables used in the LAS.
Centers may update LAS variable fields at any time, and
the OPTN requires centers to update information at least
once every 6 months. Data required for registration on the
lung transplant waiting list include diagnosis, age, height
and weight. The LAS algorithm assigns a score of zero
to patients with missing or expired data for functional
status or assisted ventilation variables. The system re-
moves candidates with an LAS of zero from the match;
they cannot receive donor lung offers. The LAS algorithm
replaces remaining missing or expired values with a ‘nor-
mal’ value for the variables of pulmonary artery systolic
pressure, pulmonary artery mean pressure (sarcoidosis di-
agnoses only), pulmonary capillary wedge mean pressure
and PCO2. The algorithm replaces missing or expired val-
ues with the ‘least beneficial’ value (i.e. yields the low-
est LAS) for the variables of diabetes, supplemental oxy-
gen, 6-min walk distance, forced vital capacity and serum
creatinine (5).
A Lung Review Board (LRB) provides peer review of cases
when transplant center physicians feel the LAS does not
reflect the estimated transplant benefit and urgency of a
waiting list candidate. Transplant centers may make re-
quests to the LRB for use of estimated clinical values (lab
values or test results) for LAS calculation when they cannot
determine real values. If a transplant center feels that the
LAS does not accurately represent a patient’s net trans-
plant benefit, it may request a specific LAS for that patient
from the LRB.
For the LAS calculation, transplant centers give each pa-
tient a primary lung diagnosis indication for transplantation
that falls into one of four diagnostic categories (Table 1).
However, patients with different diseases within the group-
ings have different characteristics. This article separately
describes outcomes for clinical diagnostic groups and LAS
diagnostic groups when deemed necessary.
Because the LAS system was implemented in the sec-
ond quarter of 2005, the 2005 data reflect results from
a mixture of the LAS and the pre-LAS systems. Though
this article uses data from the past decade, it primarily fo-
cuses on what has occurred since implementation of the
LAS system. To avoid confusion regarding pre-LAS and cur-
rent LAS organ allocation system comparisons, some anal-
yses exclude the mixed allocation system data from 2005
(e.g. data from 2006 to 2008 compared with data from
2002 to 2004). Published articles have described the ana-
lytical methods used, including adjusted analyses, for this
report (6).
LAS Variable Refinements
The OPTN Thoracic Committee receives periodic re-
ports on the performance of the LAS system from
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biostatisticians at the SRTR and OPTN. In addition to re-
viewing and voting on proposed updates to the LAS sys-
tem, the Thoracic Committee also proposes revisions to
the LAS. Proposed revisions that receive a favorable review
by the committee undergo a period of public comment. The
committee may choose to present certain LAS system revi-
sion proposals to the OPTN Board of Directors for approval.
The guidelines for patients with idiopathic pulmonary arte-
rial hypertension (IPAH), issued by the Thoracic Commit-
tee on November 21, 2006, stated that candidates with
(1) deterioration of optimal therapy, (2) right atrial pres-
sure greater than 15 mmHg and (3) cardiac index less than
1.8 L/min/m2 may qualify for an increased LAS. When a
transplant center requests an LAS modification for such a
candidate, the LRB will consider increasing the candidate’s
LAS to the 90th percentile of all lung allocation scores at
that time.
An OPTN/SRTR analysis of audited PCO2 data and LAS risk
factor and outcomes from patients first listed for lung trans-
plantation between 1998 and 2002 suggested that inclu-
sion of current PCO2 and PCO2 change data improved the
LAS estimates of patient urgency (7). In March 2007, after
undergoing review, public comment, and further discus-
sion, the OPTN Board of Directors approved modifications
to Policy 3.7.6.1 that added current and serial changes in
PCO2 to the LAS algorithm for lung transplant candidates
age 12 years and older. In December 2007, the OPTN made
available an online LAS calculator that allowed input of cur-
rent and previous PCO2 variables. Before full implementa-
tion of the revised LAS, transplant centers could make an
exception request to the LRB based on an LAS increase
due to the additional PCO2 data. The OPTN completed the
required programming and testing and implemented the
revised LAS in October 2008.
More recent analyses of retrospective OPTN audited data
have indicated improved prediction of patient urgency
based on current and serial total bilirubin values, partic-
ularly for primary lung diagnostic group B (i.e. pulmonary
vascular disease) patients with a peak total bilirubin above
1.0 mg/dL who have experienced a 50% increase in total
bilirubin within a 6-month period (8). Feedback from two dif-
ferent public comment periods indicated widespread sup-
port for this modification of the LAS algorithm. The OPTN
Board of Directors approved this revision to policy 3.7.6.1
in July 2009. However, the large anticipated expense of
collecting bilirubin data and programming this change into
the OPTN computer systems has deferred its implemen-
tation. In the interim, the Board of Directors is considering
implementing a new version of the online LAS calculator
that includes the bilirubin modifications, similar to the pro-
cedures used prior to implementation of the PCO2 modi-
fication of the LAS. In specific instances, the revised on-
line LAS calculator would provide transplant centers with
the necessary data to make exception requests to the
LRB.
Figure 1: Number of patients active on the lung transplant
waiting list by year (2006–20008) and by diagnosis group
(A–D).
Overall Waiting List and Transplant
Characteristics and Outcomes
Waiting list activity
From 1999 to 2004, over 2000 patients remained on the ac-
tive lung transplantation waiting list at the end of each year
[Table 12.1a], while the total number of candidates reg-
istered (active and inactive) progressively increased and
peaked at 3859 in 2004 [Table 1.3]. Though all registrants
accrue time on the waiting list (most important in young
pediatric candidates), only active registrants receive donor
offers. In the LAS era of 2006–2008, the number of active
wait-listed patients at year-end remained significantly de-
creased compared with the pre-LAS era (from 2163 in 2004
to 1089 in 2008; a 50% reduction). The number of active
wait-listed patients has remained around 1000 since LAS
implementation [Table 12.1a] (Figure 1), while the num-
ber of inactive wait-listed patients has declined yearly from
2057 in 2005 to 927 in 2008 [Table 12.1b]. In the LAS
era, approximately 50% of the active waiting list at year-
end consisted of patients with obstructive lung disease
(Group A), while about 30% of patients had restrictive lung
disease (Group D), 13% of patients had cystic fibrosis or
immunodeficiency disorders (Group C) and approximately
6% of patients had pulmonary vascular disease (Group
B) (Table 1, Figure 1). The active waiting list typically had
fewer than 4% of patients awaiting a repeat lung trans-
plantation (i.e. a subset of Group D). Though the absolute
number of patients in each LAS primary disease group on
the waiting list decreased over the past decade, the per-
centage in each group did not undergo significant change
[Table 12.1a].
Distribution of waiting list candidate lung
allocation scores
The median LAS at listing within the four main lung di-
agnostic groups remained relatively unchanged in 2006



































LAS at listing LAS at transplant
Source: SRTR analysis, data as of May 2009
* Includes patients aged 12+ placed on 
the waiting list on or after 5/4/2005 
with non-zero LAS at listing.
N= 1272 1272 107107 458458 59 1859
Figure 2: Median LAS at listing and
at transplant by diagnosis group
(A–D) for patients who received
lung transplants between 2006 and
2008∗.
to 2008 (SRTR special analysis, June 2009). The average
LAS increased when moving from diagnostic group A to
D. On average, the LAS at the time of wait-listing slightly
increased when last recalculated prior to transplantation
(Figure 2). Although the annual total number of waiting
candidates held steady since the inception of LAS, the
percentage of patients with an LAS of 40 or higher at year-
end steadily increased (15.6%, 16.3% and 24.5% in 2006,
2007 and 2008, respectively) after starting at a low in the
partial LAS year of 2005 (7.2%) (Table 2) [Table 12.1a].
Time to transplant
For many years prior to LAS implementation, waiting time
averaged well over 2 years because of the high ratio of the
number of waiting list candidates to the number of available
donor lungs. The decade-high median time to transplant
(TT) of 2897 days in 1999 dropped to 792 days in 2004, and
plummeted to 200 days or less in each year of 2005–2008
[Table 12.2]. The years bracketing the 2005 implementation
of the LAS showed a dramatic reduction in median waiting
time from 792 days in 2004 (95% CI, 666–965 days) to 134
days in 2006 (95% CI, 114–151 days) [Table 12.2]. In the
recent 2008 transplant cohort, one-quarter of wait-listed
patients received a transplant within 35 days.
For new lung waiting list registrants, the median TT
markedly dropped in the LAS years of 2006–2008 com-
pared with the pre-LAS years of 2002–2004. This drop oc-
curred overall and for primary lung diagnostic groups A, C
and D. Group B (i.e. pulmonary vascular disease) had the
smallest number of new registrations and did not achieve
a median in either era (SRTR special analysis, June 2009).
Median time to transplant by LAS at listing
In general, higher LAS at listing resulted in shorter median
time to transplant (SRTR special analysis, June 2009). For
patients combined from all diagnostic groups listed for a
lung transplant during 2008, those with an LAS of 50 or
higher took a median of 38 days to receive a transplant.
In comparison, those with an LAS of 40 to less than 50
had a median waiting time of 72 days. The median waiting
time increased substantially for those with an LAS lower
than 40; those with an LAS of 35 to less than 40 and 30 to
less than 35 had median TT of 150 and 324 days, respec-
tively. Fewer than 1% of patients wait-listed had a nonzero
LAS below 30. For transplant recipients with an LAS of
30 or higher (i.e. 99% of recipients [Table 12.4]), as the
LAS increased within each primary lung diagnostic group,
Table 2: Active lung waiting list patient LAS at end of year
2006 2007 2008
LAS Count Percentage Count Percentage Count Percentage
0 138 13.4 35 3.5 21 1.9
20 to <30 31 3.0 18 1.8 10 0.9
30 to <35 485 47.0 573 57.0 459 42.1
35 to <40 216 21.0 216 21.5 332 30.5
40 to <50 106 10.3 116 11.5 196 18.0
50 to <60 28 2.7 26 2.6 40 3.7
60+ 27 2.6 22 2.2 31 2.8
Total 1031 1006 1089
Source: Table 12.1a
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Figure 3: Median time to trans-
plant by diagnosis group (A–D)
and LAS group at listing for pa-
tients who received lung trans-
plants during 2006–2008.
the median waiting time for patients who received a trans-
plant decreased (Figure 3). LAS groups that include small
numbers of patients make trend analyses less precise
(Table A.1).
Greater than 99% of patients that received a single lung
transplant fell into LAS diagnostic categories A and D
(Table A.1). Most patients in Group A who had a single
lung transplant had an LAS in the range of 30 to less than
35; this group had a median waiting time about 2 weeks
longer than the bilateral lung transplant group with a similar
LAS. In contrast to the low LAS for the majority of patients
in Group A, Group D had a greater proportion of patients
distributed among the different LAS groups at listing for
both single and bilateral lung transplant recipients. Also
reversing the trend for Group A, Group D single lung re-
cipients in the most common LAS categories had shorter
median waiting times in comparison to Group D bilateral
lung recipients (data not shown).
Survival on the lung transplant waiting list
The number of registrants (active and inactive) on the lung
transplant waiting list at any point during each year (i.e. the
number at risk of dying) hovered around 5000 (high 5650;
low 4868) from 1999 to 2004 [Table 12.3]. Approximately
500 registrants (high 599; low 489) died on the waiting list
each year during that same period. The number of annual
deaths dropped from 398 in 2005 to 300, 317 and 266
in 2006, 2007 and 2008, respectively. These annual abso-
lute death counts only partially describe waiting list sur-
vival trends. Death rates, which account for the number
of patient-years at risk, provide better estimates of wait-
ing list survival. Like the death counts, the death rates for
patients on the lung transplant waiting list have dropped
since 1999. The death rates peaked at 190.5 deaths per
1000 patient-years in 1999, and dropped to a low of 103.5
in 2006 (a 46% decline) [Table 12.3]. Although the waiting
list death rate dropped following implementation of the
LAS system, it did not undergo as dramatic a decline as
the absolute number of deaths on the waiting list (Table 3)
[Table 12.3].
The absolute number of deaths and the death rate de-
creased in each primary lung diagnostic group in the LAS
era of 2006–2008 compared with the pre-LAS era of 2002–
2004. Group D had the highest annual number of deaths
pre-LAS, and it had the largest decrease in the number of
deaths when comparing LAS to pre-LAS eras. However,
Table 3: Lung waiting list reported deaths and annual death rates per 1000 patient-years at risk, 1999–2008
Year
Age this year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total
Patients 4868 5141 5374 5399 5549 5650 5269 4798 4676 4119
Deaths 599 519 532 529 489 512 398 300 317 266
Rate 190.5 152.6 149.1 145.0 131.5 135.0 115.5 103.5 125.9 128.0
Source: OPTN/SRTR Data as of May 4, 2009 [Table 12.3]
Includes patients alive on the waiting list at anytime during the year. Period at risk begins the later of January 1 or waiting list registration
and ends on the earlier of December 31, date of death, or date of removal for other reasons. Please see Technical Notes for further
details about death rate computation.
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Figure 4: Death rate for patients
placed on the lung waiting list
from May 4, 2005 to December 31,
2007, stratified by primary diagnos-
tic grouping and LAS at time of
listing.
Group D continued to have the highest annual death rate
in both eras, and Group A continued to have the lowest
death rate [Table 12.3].
Waiting list death rate by LAS
Despite the LAS prioritization of patients aged 12 and
higher for transplant, waiting list death rates increased
as the LAS categories increased (Figure 4) [Table 12.3].
Those listed with an LAS 60 or higher in groups C and
D had the highest risk of death on the waiting list (2471
and 2006 deaths per thousand patient-years at risk, respec-
tively) (Figure 4). Those listed with an LAS of 50 to less than
60 also had high waiting list death rates (1457, 611 and 739
deaths per thousand patient-years at risk for groups A, C
and D, respectively). In 2008, lung transplant candidates
had approximately 200 deaths per thousand patient-years
at risk for those with LAS of 35 to less than 50, 666 deaths
for those with an LAS of 50 to less than 60 and 1593 deaths
for those with LAS of 60 or higher. Patients with an LAS
less than 35 had the lowest death rate (184 and 59 deaths
per thousand patient-years for those with an LAS of 20 to
less than 30, and 30 to less than 35, respectively) [Table
12.3].
Deceased Donor Transplant Activity and
Recipient Profiles
The annual volume of deceased donor transplants per-
formed has increased in a stepwise fashion over the past
decade (Figure 5) [Table 12.4]. The greatest annual in-
crease occurred from 2004 to 2005, when transplants in-
creased by 21% from 1157 to 1405. Since then, the vol-
ume has remained steady. Reversing the trend observed in
Figure 5: Number of deceased
donor lung transplants, 1999–2008.

























































Source: 2009 OPTN/SRTR Annual Report, Table 12.4
* Includes both pediatric 
and adult procedures.
Figure 6: Deceased donor lung
transplant recipients in ICU at time
of transplantation, 1999–2008.
the early part of the decade, bilateral lung transplantation
became the dominant procedure and accounted for two-
thirds of all procedures performed in 2006–2008 (Figure 5)
[Table 12.4].
Lung transplant recipient demographics have changed over
the past decade [Table 12.4]. The number of recipients
65 years and older steadily increased. Whereas this age
group accounted for only 3%–5% of recipients from 1999
to 2002, it accounted for 12%, 15% and 19% of recipi-
ents in 2006, 2007 and 2008, respectively. Race and sex
demographics also changed. The percentage of white re-
cipients decreased, while the percentage of minority re-
cipients increased. In 1999, 90% of recipients were white;
this fell to 83% in 2008. During the same period, the
percentage of African American recipients increased from
6% to 9% and Hispanics increased from 3% to 6%.
These changes in recipient racial characteristics did not
clearly track with changes in primary lung diseases that
occur more frequently in certain racial groups. Until 2005,
approximately equal percentages of men and women
received a lung transplant. Coincident with the introduction
of the LAS system, a pattern of slight male predominance
emerged. In 2006, 2007 and 2008, males comprised 56%,
58% and 61%, respectively, of all recipients of lungs from
deceased donors. This trend occurred in association with
an increase in the proportion of recipients that have the
male-predominant diagnosis of IPF.
The ability to expeditiously transplant critically ill patients
under the LAS system led to a burgeoning pool of recip-
ients who came from the intensive care unit (ICU) at the
time of transplant [Table 12.4]. From 2006 to 2008, 7%
(323 of 4344) of deceased donor lung recipients required
mechanical, ventilated or organ-perfusion support at the
time of transplant, compared with 6% (181 of 3256) of
recipients from 2002 to 2004. In the past decade, the per-
centage of recipients on mechanical, ventilated or organ-
perfusion support peaked at 9% in 2008. The percentage
of patients in the ICU at transplant showed similar trends
(Figure 6); these recipients comprised 8%–9% of the re-
cipient pool from 2006 to 2008 compared with 3%–4% for
2002–2004.
In contrast to the stable proportions of patients with var-
ious diagnoses on the waiting list, the distribution of un-
derlying primary diseases among deceased donor trans-
plant recipients changed considerably in the past decade
(Figure 7) [Table 12.4]. Notably, these trends began prior
to the implementation of the LAS system. The percentage
of patients (though not the absolute number) with chronic
obstructive pulmonary disease (COPD) (excluding A1ATD)
undergoing transplantation declined and reached a nadir in
2008, when patients with COPD accounted for 29% of all
recipients compared with approximately 46% in the early
part of the decade. Showing a similar trend, the percent-
age of patients with COPD associated with A1ATD peaked
at 8% in 2002 and declined to 3% in 2008. IPAH became
an increasingly less common indication for transplantation
and accounted for only 2% of transplant procedures in
2008 compared with more than double that in the first half
of the decade. In contrast, the number and percentage of
patients with idiopathic pulmonary fibrosis (IPF) undergo-
ing transplantation steadily increased; IPF eclipsed COPD
as the leading indication for transplantation in 2007. In 2007
and 2008, one-third of transplant recipients had IPF as the
primary indication for lung transplantation. The percentage
of transplant recipients with cystic fibrosis remained rel-
atively constant, in the range of 14%–18%, throughout
the past decade. The distribution of LAS diagnostic groups
(Table 1) reflected the trends in specific primary lung diag-
noses [Table 12.4]. While the proportion of patients in lung
diagnosis Groups A and B undergoing transplantation has
declined, the proportion of patients in Group D increased,
and the percentage in Group C did not significantly
change.
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Figure 7: Primary diagnosis of de-
ceased donor lung transplant recipi-
ents, 1999–2008.
Distribution of transplant recipient LAS
Although the lung allocation system favors patients with
higher LAS, the distribution of LAS among patients receiv-
ing transplants indicates that candidates with scores of at
least 30 have had good access to organs [Table 12.4]. In
2008, 220 (15%) of recipients had an LAS of 60 or higher,
138 (9%) had a score of 50 to less than 60, 366 (25%) had
an LAS of 40 to less than 50, 353 (24%) had an LAS of 35
to less than 40 and 390 (26%) had an LAS of 30 to less
than 35. Only 11 lung recipients (0.7%) had an LAS below
30 at the time of transplant. When broken down by LAS
diagnostic group for transplants during 2006–2008, Group
D had the highest median LAS at transplant, followed by
groups C, B and A (Figure 2).
Outcomes following deceased donor transplantation
During the past decade, the most recent cohorts of de-
ceased donor lung transplantation recipients had 1-, 5-, and
10-year unadjusted survival rates of 83%, 54% and 29%,
respectively [Table 12.14]. Survival rates at 1, 3 and 5 years
posttransplant showed subtle improvement over the past
10 years [Table 12.15] (Figure 8). Since implementation of
the LAS system, 1-year posttransplant survival rates have
not significantly changed. Long-term survival data for re-
cipients in the LAS system do not yet exist.
Survival outcomes for lung recipients remain inferior to
those achieved following other solid organ transplant pro-
cedures [Table 1.13]. Heart transplant recipients have
survival rates at 1, 5 and 10 years of 88%, 75% and
56%. Deceased donor liver transplant recipients have cor-
responding survival rates of 88%, 74% and 60%.
Subgroups of patients had different unadjusted survival
rates after lung transplantation. However, adjustment for
other factors could have significantly affected the results.
Different primary lung diagnosis populations demonstrated
modest differences in survival, with a trend toward better
long-term unadjusted survival among patients with cystic
fibrosis, IPAH and COPD associated with A1ATD, com-
pared with COPD not associated with A1ATD and IPF
(Figure 9) [Table 12.14]. Compared with most other primary
lung diagnostic groups, patients with COPD not associated
with A1ATD had relatively good short-term survival and rel-
atively poor long-term survival. Alternatively, patients with
IPAH had relatively poor short-term survival and relatively
good long-term survival.
Age did not have a major impact on 1- and 5-year unad-
justed survival rates for adult recipients below the age of
65, but recipients 65 years and older had lower survival
rates than younger groups at these time points (Figure 10)
[Table 12.14]. At 10 years posttransplant, adult recipients




















Source: 2009 OPTN/SRTR Annual Report, Table 12.15
* Includes both pediatric 
and adult procedures.
Figure 8: Unadjusted patient survival for recipients of de-
ceased donor lung transplants, by year of transplant, 1999–
2007.

























Source: 2009 OPTN/SRTR Annual Report, Table 12.14
* Includes both pediatric and adult recipients. Transplants 
2006-2007 used to calculate 3 month and 1 year survival, 
2002-2007 for 5 year survival, and 1997-2007 for 10 year 
survival. The COPD groups with and without A1ATD are 
depicted separately.
Figure 9: Unadjusted patient sur-
vival for recipients of deceased
donor lung transplants, by primary
diagnosis.
years old and 65 years old and above had survival rates of
38%, 23% and 13%, respectively.
Patients who received single or bilateral lung transplants
had the same 1-year unadjusted survival of 83% [Table
12.14]. By 5 years, however, patients undergoing bilateral
transplantation had higher unadjusted survival compared
with those undergoing single lung transplantation (57%
vs. 51%; p-value < 0.001); this trend became more pro-
nounced at 10 years (37% vs. 21%; p-value < 0.001).
Patients hospitalized in the ICU at the time of transplant
had a lower unadjusted 1-year survival (57%) than hospital-
ized non-ICU patients (84%) and nonhospitalized patients
(86%) (Figure 11) [Table 12.14]. Using the metric of deaths
per thousand patient-years at risk, these recipient groups
demonstrated similar trends for the initial posttransplant
year [Table 12.7]. For patients transplanted in 2007, for ex-
ample, death rates were 699 deaths per thousand patient-
years at risk for ICU patients, 237 deaths for hospita-
lized, non-ICU patients and 172 deaths for nonhospital-
ized patients. The survival differential between the ICU and
non-ICU groups became far less pronounced at 5 and 10
years (Figure 11).
Posttransplant Survival by LAS at Transplant
By itself, the last recorded LAS prior to transplant did not
clearly predict 1-year posttransplant survival in any of the





















18 to <35 35 to <50
50 to <65 ≥65
N at risk =           325    414  1508   371                  882  1272  4075   703                1473  2351 6499   879
Source: 2009 OPTN/SRTR Annual Report, Table 12.14
*Transplants 2006-2007 used to calculate 1 
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Figure 10: Unadjusted patient sur-
vival for recipients of deceased
donor lung transplants, by recipient
age (in years).




















Source: 2009 OPTN/SRTR Annual Report, Table  12.14
*Includes both pediatric and adult recipients.  
Transp lants 2006-2007 used to calculate 90-day and 1-
year survival, 2002-2007 for 5-year survival, and 1997-
2007 for 10-year survival.  ICU – intensive care unit.
N at risk 90 d 1 yr 5 yr 10yr
Not hospitalized 2279 2279 6396 10499
Hospitalized 228 228 429 633
In ICU 211 211 374 513
Figure 11: Unadjusted patient sur-
vival for recipients of deceased
donor lung transplants, by care set-
ting at time of transplantation.
earlier, other factors may have significantly affected post-
transplant survival.
Comparison of posttransplant death rates [Table 12.7] to
waiting list death rates [Table 12.3] for different patients
with similar last-recorded LAS provides an estimate of the
survival effects of transplantation compared with contin-
ued waiting. However, this methodology does not adjust
for factors other than LAS. Such a comparison demon-
strated a survival advantage (transplantation favored over
continued waiting) for patients with an LAS of 50 or higher
(Figure 13). Candidates on the waiting list during 2008
with a last-reported LAS of 60 or greater had the high-
est waiting list death rate of all LAS groups (1593 deaths
per thousand patient-years at risk). Even though recipi-
ents with an LAS of 60 or greater at transplant had the
highest posttransplant death rate for patients transplanted
in 2007 (330 deaths per thousand patient-years at risk),
this subgroup showed the biggest reduction in death rates
(1263 deaths) when compared with those on the waiting
list in the corresponding LAS group. The subgroup with
last-recorded LAS of 50 to less than 60 prior to transplant
in 2007 had 182 deaths per thousand patient-years at risk
posttransplant, whereas the corresponding LAS group on
the waiting list in 2008 had 666 deaths (484 fewer deaths
compared with those on the waiting list). The cohorts with
an LAS of 40 to less than 50 had a posttransplant death
rate of 263 per thousand patient-years at risk and a wait-
ing list death rate of 215 (48 more deaths posttransplant
compared with deaths on the waiting list per thousand
patient-years at risk). A comparison of the posttransplant
death rate of this LAS cohort against a similarly calculated
Figure 12: One-year posttransplant
survival by diagnosis group and LAS
group at transplant for patients who
received lung transplants from May
4, 2005 to December 31, 2007.
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Figure 13: Death rates for lung pa-
tients on the waiting list in 2008 and
lung transplant recipients in 2007,
stratified by LAS.
waiting list death rate for 2007 (not 2008) showed 103
fewer deaths per thousand patient-years at risk for lung
transplantation compared with continued waiting. How-
ever, for this LAS cohort, the posttransplant death rate sub-
stantially increased from that observed in patients trans-
planted in 2005 and 2006 (approximately 180–190 deaths
per thousand patient-years at risk in those years). Patient
cohorts with LAS of 30 to less than 35, and 35 to less
than 40, had low posttransplant death rates in 2007 (157
and 199 deaths per thousand patient-years at risk, respec-
tively). However, similar LAS cohorts of patients on the
waiting list in 2008 also had low death rates (59 and 172
deaths per thousand patient-years at risk for those with
an LAS of 30 to less than 35, and 35 to less than 40,
respectively).
Observed versus expected days lived during first year
after lung transplant based on LAS modeling
Because the LAS is based in part on each patient’s es-
timated number of days lived during the first year after
transplant, an important integrity check involves the com-
parison of LAS projections against prospectively observed
days lived among patients transplanted since LAS imple-
mentation. Since transplanted patients are removed from
the waiting list, we cannot measure observed days lived
without a transplant in these same patients. Thus, we
cannot perform a similar observed versus expected com-
parison for waiting list survival.
On average, the LAS posttransplant model predicted 317
days of life in the first posttransplant year for those receiv-
ing transplants from May 4, 2005 to December 31, 2007
(SRTR special analysis, June 2009). In actuality, patients
lived an average of 324 days during their first posttrans-
plant year; that is an average underestimate by the LAS
of 7 days. Although the observed and the expected num-
ber of days lived had similar average values for the group,
the LAS did not consistently make accurate predictions for
each transplanted recipient. Ten percent of transplanted
patients had an overestimate of their first year of survival
by 180 days or more and 10% had an underestimate of
their survival of 60 days or more.
Various age subgroups had small differences in their aver-
age observed versus expected days lived in the first year
posttransplant. On average, the LAS underestimated sur-
vival by 24 days for those aged 12–17 years, and it overes-
timated survival by 4 days for those aged 65 years or older.
Other age groups had average underestimates of survival
in the 7–10 day range. For recipients aged 12–17, 90% of
predictions showed expected survival within 3 months of
observed survival, and expected survival typically underes-
timated the observed survival. Older age groups showed
much greater variability in observed versus expected sur-
vival. For recipients aged 65 years and older, the middle
80% of differences showed overestimates in days lived as
high as 222 days and underestimates as much as 61 days.
LAS diagnostic subgroups showed small average underes-
timates (expected value less than observed value) by LAS
for days lived during the first year posttransplant; 10 days
for Groups B and C, 8 days for Group A and 5 days for
Group D. In terms of variability in prediction accuracy, LAS
had the lowest variability for Group C patients and had the
highest variability for Group B patients. For Group C, 10%
of transplanted patients had an overestimate of their first
year of survival by 96 days or more and 10% of patients
had an underestimate of 54 days or more. For Group B,
10% of patients had an overestimate of their first year of
survival by 257 days or more and 10% had an underesti-
mate of 81 days or more. Groups A and D had variability in
observed minus expected days lived similar to that seen in
the overall population of recipients.
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Retransplantation
Parallel with the overall decline in active candidates on the
waiting list since LAS introduction, the number of candi-
dates listed for retransplantation also declined, falling from
a range of 56–67 patients at the end of each year prior
to 2005 to 45, 34 and 35 candidates for 2006, 2007 and
2008, respectively [Table 12.1a]. Retransplant candidates
accounted for 3%–4% of the total waiting list population
during 2006–2008, compared with 2%–3% in the pre-LAS
era of 1999–2004.
Though death rates on the waiting list declined for all ma-
jor disease groups awaiting primary transplantation since
implementation of the LAS system, the opposite trend has
occurred for patients awaiting retransplantation. The death
rate for those awaiting retransplantation increased earlier
in the decade, stabilized in the year and a half prior to and
after LAS implementation, and then increased again in the
next 2 years. The roughly 370 deaths per one thousand
patient-years at risk recorded in 2007 and 2008 for retrans-
plantation candidates represented a 68%–200% increase
compared with rates from 1999 to 2004 [Table 12.3].
The indications for retransplantation have remained rel-
atively consistent over the past decade (SRTR special
analysis, June 2009). Primary lung transplant recipients
have bronchiolitis obliterans syndrome (BOS) and primary
graft failure as the two most common diagnoses lead-
ing to relisting. In 2008, 61% of primary recipients listed
for retransplantation had BOS as the relisting diagno-
sis while 15% had primary graft failure as the diagno-
sis. Diagnostic misclassification inherent in the data col-
lection system likely resulted in underestimation of the
number of patients in these categories, since numerous
patients had their diagnosis classified under alternative
nonspecific diagnostic categories such as ‘graft failure—
other’ and ‘graft failure—obstructive’ or under the initial
primary diagnosis (e.g. COPD/emphysema). Patients listed
for retransplantation in 2006, 2007 and 2008 had a mean
LAS of 47, 45 and 52 (median 39, 40 and 42), respec-
tively. These scores occurred within the upper quintile for
all patients on the active waiting list during those years
[Table 12.1a].
The interval from the primary transplant to retransplanta-
tion has remained relatively constant over the past decade,
with a mean of 1478 (median 1154) days during the pre-
LAS era of 1999–2004 and 1433 (median 1038) days for the
LAS era of 2005–2008 (SRTR special analysis, June 2009).
In contrast, waiting times from relisting to retransplanta-
tion have fallen considerably since implementation of the
LAS system. The mean waiting time of 336 (median 146)
days for the pre-LAS era of January 1, 2003 to May 3, 2005
declined to 190 (median 45) days for the LAS era of May 4,
2005 to December 31, 2007 (SRTR special analysis, June
2009).
A significant and sustained increase in the number of pa-
tients undergoing retransplantation occurred after the in-
troduction of the LAS system. From 2006 to 2008, 211
patients underwent retransplantation (99 single, 112 bi-
lateral), compared with only 94 recipients for the period
from 2002 to 2004 (46 single, 48 bilateral) [Table 12.4].
The annual number of retransplantation recipients peaked
in 2007 at 84, declining slightly in 2008 to 73 recipients.
Retransplantation accounted for 5.7% of all recipients in
2007 and 4.9% in 2008, compared with 1.9%–3.3% of
transplant volume in the pre-LAS years of 1999–2004.
Unadjusted 1-year survival rates associated with retrans-
plantation improved slightly over the past decade; increas-
ing from 63% for the 1999–2004 era to 70% for the 2005–
2007 era (SRTR special analysis, June 2009). Nonetheless,
the 1-year unadjusted survival rate following retransplan-
tation remained inferior to the 83% rate achieved with pri-
mary transplantation in the LAS era [Table 12.14]. Sim-
ilarly, between 2005 and 2007, death rates for primary
transplant recipients ranged from 174.7 to 198.5 deaths
per thousand patient-years at risk [Table 12.7] compared
with 231.5–551.4 deaths per thousand patient-years at risk
for retransplant recipients [Table 12.7]. Patients with differ-
ent indications for retransplantation had different survival
rates. Lung recipients retransplanted for BOS, by definition
diagnosed more than 3 months after the primary trans-
plant, had superior unadjusted 1-year posttransplant sur-
vival compared with patients undergoing early and urgent
retransplantation (within 90 days of initial transplantation)
for primary graft failure: 71% (95% CI, 61.1%–78.1%) for
112 patients retransplanted for BOS between May 2005
and December 2007 compared with 54% (95% CI, 24.8%–
76.0%) for 13 patients urgently retransplanted for primary
graft failure during that time (SRTR special analysis, June
2009).
Previous lung transplantation does not specifically affect
LAS. However, diagnoses commonly used for retransplant
candidates (e.g. primary graft failure, BOS) place these
patients in LAS diagnostic Group D. The LAS overestimated
days lived in the year after retransplantation by an average
of 6 days. Ten percent of retransplantation recipients had
projections overestimated by 231 days or more and 10%
had projections underestimated by 83 days or more (SRTR




The use and types of an induction regimen for lung
transplant recipients have evolved over the last decade
(Figure 14) [Table 12.6a]. Induction therapy use more than
doubled from 31% in 1999 to 63% in 2008. Polyclonal
antilymphocyte antibody induction therapy declined over
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Source: 2009 OPTN/SRTR Annual Report, Table 12.6a.
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Figure 14: Trends in induction im-
munosuppression for lung trans-
plantation, 1999–2008.
the past decade. Use of a non-rabbit antithymocyte glob-
ulin (i.e. equine ATG/NRATG/NRATS), the most commonly
prescribed type of perioperative induction agent in 1999,
trended downward from 13% in 1999 to 7% in 2008. Rab-
bit derived antithymocyte globulin (i.e. thymoglobulin) has
shown fluctuation and a slight downward trend from a high
of 8% in 2002 to 5% in 2008. Overall, monoclonal antilym-
phocyte antibody induction therapy has increased over the
past decade. Use of the interleukin-2 (IL-2) receptor antag-
onists, basiliximab or daclizumab, has almost quadrupled
over the past decade to account for 43% of all induction
therapy used in 2008. Basiliximab became the most com-
monly used induction agent in lung transplantation in 2002.
Alemtuzumab had a marked increase in use in the last half
of the past decade, increasing tenfold from 0.9% of recip-
ients in 2003 to 9% in 2008. Muromonab-CD3 (i.e. OK-T3)
had limited use over the past decade (0.7% in 2008), and
the manufacturer discontinued its production in 2009.
Maintenance immunosuppression before hospital
discharge, after lung transplantation
The use of the two main calcineurin inhibitors before
the first hospitalization discharge showed divergent trends
over the past decade. The use of cyclosporine (CyA) for
maintenance therapy decreased steadily from 67% in 1999
to 8% in 2008. Conversely, use of tacrolimus (Tac) in-
creased over the same period, from 30% in 1999 to 89%
in 2008 (Figure 15) [Table 12.6e]. Use of the two main
classes of antimetabolite cell cycle inhibitors before lung
transplant hospitalization discharge also showed divergent
trends over the past decade. Azathioprine (Aza) use de-
clined steadily from 64% in 1999 to 28% in 2008, while
mycophenolate agent (mycophenolate mofetil [MMF] and,
much less commonly, mycophenolate sodium [MPA]) ad-
ministration increased from 28% in 1999 to 63% in 2008.
The use of sirolimus, a mammalian target of rapamycin
(MTOR) kinase inhibitor, peaked at 4% in 2001, and then
decreased to only 0.4% in 2008. The vast majority of pa-
tients (98% in 2008) continued to receive glucocorticoids
prior to discharge from the hospital.
At the time of the first hospital discharge after transplan-
tation, 58% of recipients received Tac/MMF or Tac/MPA
(the fastest growing regimen over the past decade), and
23% received Tac/Aza [Table 12.6d]. CyA/Aza, the most
common regimen from the 1980s to the early 2000s, ac-
counted for only 4% of regimens in 2008. CyA/MMF, which
peaked at 18% in 2001, accounted for only 3%.
Maintenance regimen change and discontinuation for
lung transplantation
Almost all patients used glucocorticoids throughout follow-
up after transplantation. Regarding use of immunosup-
pressive agents other than glucocorticoids over time
(Figure 16) [Table 12.6h], the greatest changes generally
occurred in the first year after transplantation. For recipi-
ents in the 2006 cohort that used Tac/MMF or Tac/MPA as
the original discharge regimen, 61% of them still used it
at 3 years after transplantation (the highest for all of the
regimens). For recipients initially treated with the Tac/Aza
regimen, only 28% continued its use. For the CyA/MMF or
CyA/MPA group, only 18% continued its use. The highest
rate of regimen attrition occurred in patients initially treated
with CyA/Aza, of which only 16% continued its use.
Acute lung transplant rejection treatment
Over the past decade, antirejection therapy use fluctuated
during the first posttransplant year. In patients transplanted
in 2007, treatment for acute rejection in the first posttrans-
plant year in 380 patients out of a total cohort of 1471
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Source: 2009 OPTN/SRTR Annual Report, Table 12.6e.
*Includes both pediatric and adult procedures.
Mycophenolate agents includes mycophenolate 
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Figure 15: Trends in maintenance im-
munosuppression during lung trans-
plantation hospitalization, 1999–2008.
(26%) decreased compared with the 10-year high of 46%
in 2001 [Table 12.6i]. Of those in the 2007 transplant co-
hort who received treatment, the great majority of patients
(93%) received acute augmented glucocorticoid therapy.
Of those treated, only 14% received an antilymphocyte
antibody preparation, and most received a polyclonal an-
tilymphocyte antibody; 6% received rabbit antithymocyte
globulin and 5% received non-rabbit antithymocyte globu-
lin (Figure 17) [Table 12.6i].
Donor Characteristics
Deceased lung donors have shown a relatively stable age
distribution over the past decade [Table 2.7]. Donors in
the 18–34 year-old cohort have provided the most lungs
(46% in 2008), while the second most common donors
came from the 35–49 year-old cohort (25% in 2008). De-
ceased lung donors have also had relatively stable eth-
nicity, race and sex distribution, with the 2008 cohort
62% white, 19% African American and 16% Hispanic.
Male donors made up 61% of the 2008 cohort. Donor
blood type distribution remained constant over the past
decade, with 52% type O, 35% type A, 11% type B
and 2% type AB. In 2008, donors most commonly died
from head trauma (48%), cerebrovascular injury (36%)
or anoxia (12%), while the specific mechanisms that led
to donor death most commonly consisted of intracranial
hemorrhage/stroke (38%), blunt injury (26%) and gun-
shot/stab wounds (20%).
Of all deceased donors, donation after brain death (DBD)
donors provided the most lungs for recipients, while
donation after cardiac death (DCD) donors have provided
few. Kidney and liver transplantation have seen much
higher rates of DCD compared with lung transplantation.
Figure 16: Percentage of lung transplant
recipients continuing initial maintenance
immunosuppression at 1, 2 and 3 years
posttransplant, for four most common
regimens 2006.
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Figure 17: Antilymphocyte antibody
therapy for rejection episodes in first
year following lung transplantation,
1998–2007.
Centers first reported use of lungs from DCD donors in
2001. Though the highest number of DCD lung transplants
(19 total cases) occurred in 2008, it only represented 1%
of the total number of recipients of deceased donor lung
transplants that year [Table 2.7].
Lobar lung transplantation from living donors decreased
steadily over the past decade. The number of living donors
peaked at 58 (representing 7% of all lung donors) in 1999,
and decreased to six cases in 2007 and zero cases in 2008
[Table 2.11]. The greatest decline occurred between the
2004 and 2005 cohorts.
Some interesting and important trends have occurred in
deceased donor organ use over the past 10 years [Table
2.18]. The total number of deceased donor lungs used for
transplantation on a yearly basis continued a decade-long
increase to a high of 2534 lungs from a high of 1388 donors
in 2008. This represents a 91% increase in transplanted
lungs and a 79% increase in total lung donors since 1999.
For the metric of organs transplanted per donor (OTPD), the
lung-specific OTPD counts each lung separately, whereas
the percentage donating a lung(s) methodology counts sin-
gle or double lung donation only once for each donor. The
lung-specific OTPD peak of 0.32 in 2008 represented a
39% increase compared with 1999. Specifically looking at
DBD, the OTPD for lungs in 2008 was 0.35 compared with
0.23 in 1999 (a 52% increase). Not surprisingly, in view of
the limited experience and relatively slow adoption of DCD
lungs by the lung transplant community, the lung OTPD for
DCD donors was only 0.04 (representing a total of only 34
transplanted lungs in 2008). For all deceased donors of any
organ, the percentage donating a lung(s) increased from
13% in 1999 to a decade high of 17% in 2008. The largest
1-year interval increase in the number of lung donors and
lung donor conversion rates occurred in the 2004–2005 in-
terval (a 21% lung donor increase and a 13% conversion
rate increase).
The SRTR recently conducted new analyses (SRTR special
analysis, June 2009) to assess the distribution of donor
lungs to the respective recipient age groups in the pre-
LAS and LAS eras (e.g. 1 year before and all years after
LAS implementation). Since advanced age accompanies
the LAS diagnostic group with highest average LAS (i.e.
Group D), and LAS prioritizes lung transplantation, the dis-
tribution of donor lungs has shifted from younger to older
recipients. For lungs from donors aged 18–34, only 6%
went to recipients aged 65+ years before the implemen-
tation of the LAS system. However, in the 3.5 years since
implementation of the LAS system, a shift in the donor–
recipient age distribution occurred. In the last half of 2008,
21% of lungs from donors aged 18 to less than 35 years
went to recipients aged 65 years or older, compared with
6% in the recent pre-LAS era (a 250% increase). Similarly,
19% of lungs from donors aged 35 to less than 50 years
went to recipients aged 65 years or older in the last half
of 2008, compared with 6% in the recent pre-LAS era (a
217% increase).
Pediatric Lung Transplantation
Trends in pediatric lung transplantation during the past
decade, particularly since LAS inception, continued to re-
flect limited growth. Pediatric lung allocation had impor-
tant interactions with adult lung allocation based on issues,
such as LAS allocation for older pediatric candidates, pref-
erential allocation of pediatric lungs to pediatric candidates
and size matching.
Indications for pediatric lung transplant
In 2008, cystic fibrosis, with its associated bronchiectasis
and obstructive lung disease, remained the most common
indication for lung transplantation in children (age less than
18 years) and accounted for nearly 70% of pediatric lung
transplants (SRTR special analysis, June 2009). More than
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Source: 2009 OPTN/SRTR Annual Report, Tables  12.1a, 12.3 - 12.4.
Figure 18: Pediatric patients listed for
lung transplant, deaths on the waiting
list and transplanted, 1999–2008.
90% of pediatric lung transplants for cystic fibrosis oc-
curred in adolescents (age 12 to less than 18 years) in
2008. Transplantation for cystic fibrosis rarely occurred be-
fore age 6. The percentage of pediatric lung transplants for
pulmonary hypertension, either primary or associated with
congenital heart disease, decreased steadily through the
decade and accounted for less than 10% of transplants
in 2008. Recently, pulmonary parenchymal disease, mainly
related to surfactant abnormalities, became the most com-
mon (80%) indication for lung transplantation for children
younger than 6.
Pediatric waiting list and transplant activity
The number of pediatric candidates active on the lung
transplant waiting list at the end of 2008 remained essen-
tially unchanged since LAS inception. However, this repre-
sented a significant decline from a pre-LAS average of 130
(Figure 18) [Table 12.1a]. From 2007 to 2008, the number
of adolescents active on the lung transplant waiting list
doubled from 15 to 31, while the number of pediatric can-
didates aged 0 to less than 12 years dropped from 28 in
2007 to 13 in 2008. The 45 to 54 deceased donor pedi-
atric lung transplants performed annually did not apprecia-
bly change over the past half decade [Table 12.4]. Centers
did not report any pediatric living donor lung transplants in
2008 [Table 2.11].
Only 14 deaths occurred on the pediatric lung transplant
waiting list (active and inactive) during 2008, compared
with 21 in 2007 (Figure 18) [Table 12.3]. A reduction in
overall adolescent deaths accounted for most of this de-
crease; an annual average of 13 adolescent candidate
deaths occurred in 2005–2007, while only four adolescent
candidate deaths occurred in 2008. During 2008, the 1 to
less than 6 year-old age group and the 6 to less than 12
year-old age group had waiting list death rates (candidate
deaths per one thousand patient-years at risk) of 416.2 and
151.1, respectively, well above the average rates observed
during the past 5 years and the highest rates observed
since LAS inception. In contrast, adolescents on the active
waiting list had a death rate of only 53.5, the lowest dur-
ing the decade and the lowest for any age group in 2008.
During the last 5 years, candidates less than a year old had
only one waiting list death reported.
The ratio of the percentage of patients on the waiting list
(active and inactive) who died to the percentage of pa-
tients who received a transplant (i.e. waiting list death to
transplant ratio) provides another metric for assessing lung
allocation effectiveness. The ratio decreased for both pe-
diatric and adult lung transplant candidates over the past
decade. Since LAS inception, the ratio remained relatively
stable for children while it continued to decline for adults
(Figure 19).
Adult wait-listing and transplantation numbers have in-
creasingly overshadowed those of children. In 1999, chil-
dren represented 5% of the lung transplant active waiting
list [Table 12.1a] and 4% of the transplants [Table 12.4]; in
2008, children made up 4% of the active waiting list [Ta-
ble 12.1a] and 3% of the transplants [Table 12.4]. Of new
pediatric registrants on the active lung waiting list, only
adolescents have median time to transplant data available
for each year since LAS inception. The TT metric for ado-
lescent candidates declined steadily since implementation
of the LAS, from 521 days in 2005 to 117 days in 2008.
Adolescent pediatric candidates had a median TT shorter
than adult age subgroups, except for those 65 years and
older [Table 12.2].
Pediatric lung allocation
OPTN policy adopted in conjunction with implementation
of the LAS directs lungs from pediatric donors first to pe-
diatric candidates ages 0 to less than 12 years and then to
those 12 to less than 18 years. This policy led to a modest
increase in the percentage of age 0 to less than 12 years
old donor lungs transplanted into children; from 70% in the
year preceding LAS implementation to between 80% and
89% in the first 3 years after. Within the 0 to less than 12
years group, the relatively small number of donors or the
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Figure 19: Ratio of lung waiting list
deaths to transplants, pediatric and
adult, 1999–2008.
decrease in the number of actively listed children may have
caused an anomalous drop (to 50% in the most recent
[partial year] cohort) in same age group donor–recipient
matching. The percentage of lungs from adolescent donors
transplanted into children (predominantly adolescents)
fluctuated and had a modest increase since LAS imple-
mentation, from 8% the year before implementation to
as high as 14% in the most recent cohort (SRTR special
analysis, June 2009).
Pediatric lung transplantation outcomes
In the 2006 and 2007 cohorts, pediatric deceased donor
lung transplant recipients had adjusted 1-year survival
(83%–97%) comparable to adult lung transplant recipients.
Of the four pediatric age groups (<1 year, 1 year to <6
years, 6 years to <12 years, and 12 years to <18 years),
children aged 6 to less than 12 years had the highest 1-
year adjusted survival (97%) and adolescents had the next
highest (95%). In a cohort of mostly pre-LAS recipients,
children 6 to less than 12 years of age still had the highest
adjusted 5-year survival (66%) out of all pediatric recipi-
ents. In contrast, adolescent recipients from a similar era
had the worst 5-year survival (38%) of any pediatric or adult
age group [Table 12.12].
Heart–Lung Transplantation
The 91 heart–lung transplant candidates (active and inac-
tive) on the waiting list at the end of 2008 had a broad
spectrum of baseline primary cardiopulmonary disorders
that included the Eisenmenger syndrome spectrum of dis-
eases (55%) and IPAH (15%). Mixed diseases, such as
combinations of coronary artery disease and IPF, or valvular
heart disease and COPD, occurred in 14% of candidates.
Patients with sarcoidosis represented 4% of candidates
and combined organ congenital diseases represented 9%
[Tables 13.1a and 13.1b, SRTR Special Analysis].
At the end of 2008, the heart–lung transplant active wait-
ing list consisted of only 33 (36%) of the 91 heart–lung
candidates [Table 13.1a]. Ten of the 33 active candidates
(30%) and 48 of the 58 inactive candidates (83%) had been
on the list for more than 2 years [Tables 13.1a and 13.1b].
The death rate for candidates (active and inactive) on the
heart-lung transplant waiting list fluctuated widely over the
past decade, although the rate showed a gradual decline
[Table 13.3]. Candidates on the heart–lung transplant wait-
ing list during 2008 had a death rate (155 per thousand
patient-years at risk; 95% CI 112.6–143.4) lower than that
of patients on the heart-only transplant waiting list (170 per
thousand patient-years; 95% CI 154.0–185.6) and higher
than that of patients on the lung-only transplant waiting
list (128 per thousand patient-years; 95% CI 76.5–233.1)
[Tables 11.3, 12.3, and 13.3].
The number of heart–lung transplant recipients declined
from 51 in 1999 to 27 in 2008 [Table 13.4]. Over the
past 5 years, only two transplant centers performed an
average of two or more heart–lung transplants per year
[Table 13.17]. Recipients of heart–lung transplants rarely
underwent heart–lung retransplantation. The 58 heart–lung
transplant recipients in 2007–2008 consisted of nine pedi-
atric patients (16%), 27 hospitalized patients (47%) and
17 patients using some form of mechanical, ventilated or
organ-perfusion support (29%) [Table 13.4]. Of the 58 re-
cipients of heart–lung transplants in 2007–2008, 33% had a
diagnosis of Eisenmenger syndrome, 24% had IPAH, 9%
had sarcoidosis and 7% had combined-organ congenital
diseases. Patients with primary cardiac lesions with sec-
ondary pulmonary hypertension represented 7% of cases.
Mixed diseases, such as combinations of valvular heart dis-
ease and IPF or dilated cardiomyopathy and cystic fibrosis
represented 12% of candidates. Patients with dual organ
consequences of cancer-related therapy accounted for 7%
of cases (SRTR special analysis, June 2009).
Recipients of heart–lung transplantation in the past decade
had adjusted posttransplant survival rates of 86% at 3
months, 81% at 1 year, 45% at 5 years and 29% at 10 years
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[Table 13.12]. Though these rates more closely approxi-
mated the survival rates of lung-only transplant recipients
than heart-only recipients, heart–lung transplant recipients
had lower survival than patients undergoing other types of
solid organ transplantation [Tables 5.12c, 6.12, 7.12, 8.12,
9.12, 10.12, 11.12, 12.12 and 13.12].
Discussion
The number of adult lung transplants significantly in-
creased over the past decade, while the number of pedi-
atric lung transplants and heart–lung transplants remained
low. Significant changes in listing practices, characteristics
of recipients transplanted and treatment approaches have
occurred in the LAS era compared with before. Associ-
ated with implementation of the LAS system, the number
of active waiting list patients, the waiting times for lung
transplantation and the death rates on the waiting list de-
creased. One-year survival after lung transplantation did
not significantly change in the recent pre-LAS and the LAS
eras. The LAS system has produced intended and unin-
tended consequences, and the long-term effects remain
unknown.
Though the LAS system had overall positive effects in
comparison to the pre-LAS system, it demonstrated dif-
ferential effects upon common diagnostic subgroups that
included COPD (non-A1ATD and A1ATD), cystic fibrosis,
IPF and IPAH. Waiting time for transplantation decreased
for all major diagnostic subgroups in conjunction with a
reduced number of patients on the waiting list and a pre-
sumed decrease in the practice of early listing. The in-
crease in transplant priority for patients with IPF and the
decrease for patients with COPD led to increased trans-
plants in patients with IPF and decreased transplants in
patients with COPD. Patients with IPAH on the lung trans-
plant waiting list, on average, had a lower priority than pa-
tients with cystic fibrosis or IPF. Some small single center
studies (9,10), a multi-center study (11), and some studies
of SRTR data (12–14) supported our findings that the distri-
bution of diagnoses of patients undergoing lung transplant
changed in association with implementation of the LAS
system. One study of SRTR data did not show statisti-
cally significant changes in the distribution of diagnoses,
but the trends remained apparent, especially for an in-
crease in the proportion of patients undergoing transplant
for IPF and a decrease in those undergoing transplant for
COPD (15).
This SRTR article showed that the number and proportion
of patients with IPAH wait-listed and undergoing transplant
remains dwarfed by the other primary lung diagnoses.
Compared with other LAS diagnostic groups, Group B (in-
cluding the IPAH patients) had the highest variability in ob-
served versus predicted posttransplant survival. A recent
investigator-initiated study of data from the SRTR for adults
wait-listed for lung transplantation between 2002 and 2008
suggested that patients with IPAH had a lower likelihood
of undergoing transplant compared with those with IPF; a
greater risk of death on the waiting list than patients with
COPD; and a posttransplant mortality not significantly dif-
ferent from patients with the other primary lung diseases
(14). Though a guideline for modifying the LAS for pa-
tients with IPAH exists, refinements of the system for dis-
tributing donor lungs will require additional data collection
and analyses. However, the ability to generate reliable and
accurate models for patients with IPAH remains limited by
the small number of patients.
Another study that only included 1 year of post-LAS data
found that posttransplant hospital length of stay shortened
after implementation of LAS (12), while a multicenter study
found that ICU length of stay increased (11). The multicen-
ter study also found that rates of primary graft dysfunction
(PGD) increased after implementation of the LAS system
(11), while another single center study did not see such an
increase (10).
Since the LAS system facilitated the ability to perform ex-
pedited transplantation, the number of critically ill patients
transplanted increased. These patients typically had high
LAS because of high supplemental oxygen requirements
and/or need for mechanical ventilation; they, therefore, had
preferential access to donor lungs. However, critical illness
may have resulted in profound deconditioning, malnutrition
or other significant complications that increased the risk of
poor early outcomes after transplant. Accordingly, patients
who came from the ICU had lower short-term posttrans-
plant survival in comparison with less acutely ill popula-
tions. Nonetheless, waiting list death rates compared with
posttransplant death rates for patients with the highest
LAS suggested that this group of patients had the largest
short-term transplant benefit.
Advanced age became less of a barrier to transplantation
over the past decade, and almost 20% of recipients in 2008
were at least 65 years old. Such recipients had a higher
first-year posttransplant mortality than any other age group,
and longer-term follow-up also showed a higher mortality
rate.
The annual number of patients undergoing retransplanta-
tion roughly doubled since the introduction of the LAS
system. Both acute (e.g. PGD) and chronic (e.g., BOS)
forms of graft failure placed retransplant candidates into
LAS diagnostic Group D. Compared with the pre-LAS era
in which long waiting times often precluded retransplan-
tation, retransplant candidates in the LAS era often had
short waiting times because of very high LAS. In the
pre-LAS and LAS eras, patient survival after retransplan-
tation remained lower than the survival of patients af-
ter primary lung transplantation, and retransplantation for
PGD had even lower survival rates than retransplanta-
tion for BOS. The increased use of retransplantation in
the setting of ongoing organ shortages raises ethical
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issues. The Thoracic Committee may assess the appropri-
ateness of adding factors to the posttransplant portion of
the LAS model to correct for the worse outcomes associ-
ated with retransplantation compared with primary trans-
plantation, once they obtain sufficient data. In addition,
the committee could consider separately grouping retrans-
plant candidates from other Group D candidates. However,
similar to the scenario with IPAH candidates, the ability to
generate reliable and accurate models for retransplant can-
didates remains limited by the small number of patients.
Overall, patients undergoing lung transplantation experi-
enced modest improvements in both short- and long-term
survival over the past decade, though barely half of re-
cipients reached the 5-year milestone and less than a third
achieved 10-year survival. Multiple studies corroborate this
article’s finding that overall posttransplant mortality did not
increase after implementation of LAS (10–14). Lung trans-
plantation has consistently demonstrated inferior interme-
diate and long-term survival compared with renal, heart
and liver transplantation. Pre-LAS and LAS data suggest
that the increasing number of critically ill, elderly, and pre-
viously transplanted candidates undergoing lung transplan-
tation may drive down the overall survival of recipients. Op-
timizing outcomes in these higher risk groups may require
more careful selection of candidates (16–17).
The limited growth in pediatric lung transplantation com-
pared with that seen in adults during the LAS era illus-
trates one of the most notable pediatric lung transplant
trends identified in this report. Historically, children un-
derwent lung transplantation primarily for cystic fibrosis-
related lung disease. However, children with cystic fibro-
sis have had a significantly increased median survival over
the decade. The upward shift of the average age at trans-
plant for children with cystic fibrosis provides the most
likely explanation for a lack of growth in transplantation for
children.
Divergent trends in waiting list outcomes occurred in chil-
dren and adolescents in the LAS era. In contrast to pe-
diatric candidates less than 12 years of age (donor lung
allocation prioritized by time on the waiting list), adoles-
cent candidates (donor long allocation prioritized by LAS)
had a reduction in waiting list mortality. Compared with
younger candidates, adolescents also had a shorter wait-
ing time to transplant, likely because of a combination
of reduction in active candidates (i.e. adolescents are no
longer listed solely to gain time on the waiting list) and
improved access to transplant as a result of the LAS sys-
tem. In spite of excellent 1-year survival, long-term out-
comes in adolescents remained poor in comparison with
other age groups, and the reasons for this disparity remain
unclear.
The ratio of the percentage of patients on the waiting list
who died to the percentage who underwent transplant did
not decrease in children after implementation of the LAS
system. However, this metric for assessing lung allocation
effectiveness decreased in adults. These trends imply that
the current LAS system may have greater effectiveness in
adults than children. Recently, the OPTN Board of Direc-
tors approved modifications of the lung allocation policy to
create a simple status system and provide broader geo-
graphic sharing of lungs from donors aged 0 to less than
12 years to all children (18). Implementation of this pol-
icy should improve access to transplantation and lead to
decreased waiting time and death rates on the waiting list
for young children.
The Thoracic Committee originally intended that the donor
lung allocation algorithm and model (i.e. LAS) remain a
work in progress, and it planned to update the model based
on prospective data collection. After originally creating the
LAS model based on data from almost a decade ago, the
SRTR and the OPTN Thoracic Committee have begun ad-
dressing several topics related to updating the LAS based
on more recent data. Because the LAS moved patients
with higher waiting list mortality from the candidate pool
to the lung transplant recipient pool, the projections of un-
observed waiting list deaths based on data from patients
remaining on the waiting list has raised some statistical
modeling challenges. New models based on an LAS co-
hort address this issue by placing higher weight on follow-
up information from nontransplanted candidates who have
characteristics similar to patients who have gone on to re-
ceive a transplant (19). The committee also expected that
the algorithm would change risk factors and adjust haz-
ard ratios or variable weights when appropriate. The SRTR
and the Thoracic Committee continue to explore alternative
ways to characterize risk based on existing LAS variables.
For example, during initial LAS development, the model did
not have serial changes in predictor data available. Based
on more recently available serial change data, the first sub-
stantive change in the LAS consisted of the inclusion of
PCO2 and PCO2 change data in the model. Recent analyses
showed that the addition of bilirubin and bilirubin change
variables to the model improved its predictive ability. How-
ever, questions exist about appropriate funding choices for
programming new policy; the LAS model has not yet incor-
porated the bilirubin variables.
Although the need for organs continues to outstrip de-
mand, donor lung transplant volume significantly increased
in the early portion of the past decade and then stabi-
lized more recently. The decade’s largest 1-year interval
increase in the number of lung donors and lung donor con-
version rates occurred in 2004–2005, around the time of
LAS system implementation. The increase in lung trans-
plant volume occurred despite preferential use of bilateral
transplantation, a trend that had the potential to rapidly con-
sume the limited donor pool. Multiple events contributed
to the increase in the OTPD, and lungs had the greatest
increase of any organ in the last half of this decade. Though
the improved efficiency of lung placement at a lower po-
sition on the match run (i.e. fewer phone calls needed to
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place the organ and less time elapsed) with the LAS sys-
tem may have increased the OTPD, at least three other
factors likely played an equal or greater role: (1) the De-
partment of Health and Human Services sponsored Organ
Donation Breakthrough Collaborative (first initiated in 2003)
increased donor identification and consent rates (20–21);
(2) Organ Procurement Organizations (OPOs) standardized
and improved the management of potential donors; and
(3) transplant centers increasingly use expanded criteria
donors (ECD).
The quality of this report depends on the quality of the data
in the SRTR. The SRTR database contains robust informa-
tion that covers a broad range of areas. However, inherent
limitations in prospective registries exist. Misclassification
of diagnoses occurs based on the limited clinical informa-
tion available, data entry errors, and the requirements of
the classification system. Long-term data do not exist yet
for the LAS system. Small sample sizes for uncommon
conditions limit the ability to do some subgroup analyses.
Though the SRTR has relatively high-quality survival data,
the system does not collect quality of life data and there-
fore does not have the ability to address quality-adjusted
survival. The predictive models that use the SRTR data also
have inherent limitations, and the models require ongoing
validation and refinement.
Changes to the LAS system and to geographic sharing
of donor lungs will continue to affect the distribution and
types of candidates undergoing transplantation and their
outcomes. Continued surveillance and refinement of the
transplant system will hopefully lead to improved system
efficiency and patient outcomes.
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Table A.1: Sample size for median time to transplant by LAS diagnostic group and LAS group at listing in years 2006–2008
LAS primary LAS group All lung Single lung Bilateral lung
diagnostic group at listing transplant patients∗ transplant patients transplant patients
N N N
A 20−<30 33 12 21
30−<35 996 422 574
35−<40 184 62 122
40−<50 44 9 35
50−<60 5 0 5
60+ 10 2 8
ALL 1272 507 765
B 20−<30 6 1 5
30−<35 53 1 52
35−<40 29 2 27
40−<50 17 3 14
50−<60 2 0 2
60+ 0 0 0
ALL 107 7 100
C 20−<30 3 0 3
30−<35 131 1 130
35−<40 208 2 206
40−<50 83 1 82
50−<60 17 0 17
60+ 16 0 16
ALL 458 4 454
D 20−<30 8 4 4
30−<35 287 136 151
35−<40 510 268 242
40−<50 655 283 372
50−<60 187 71 114
60+ 212 73 139
ALL 1859 835 1022
∗See Figure 3.
Includes patients aged 12+ placed on the waiting list on or after May 4, 2005 with nonzero LAS at listing.
Two patients in group D did not have single/bilateral transplant type specified, so they are excluded from the single/bilateral transplant
column data.
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